ReviewCureus2025
Shared Decision-Making in the Management of Schizophrenia: A Systematic Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia is a chronic mental disorder that affects an individual's emotional, cognitive, and behavioral well-being. Schizophrenia is characterized by poor treatment adherence, frequent relapses, and worsening symptoms, often leading to increased hospitalizations. Shared decision-making (SDM) has been proposed to enhance adherence by involving patients and their caregivers in collaborative treatment decisions. However, the impact of SDM on adherence, quality of life, and mental health outcomes remains uncertain. This review evaluates the effectiveness of SDM interventions on treatment adherence in individuals with schizophrenia and explores health-related outcomes, including quality of life, mental health, self-efficacy, trust in healthcare providers, and self-regard. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, PubMed, CINAHL, and Web of Science were systematically searched. Randomized controlled trials, quasi-experimental, and observational studies assessing adherence were included. Data extraction was performed by two independent reviewers, and study quality was assessed using the Cochrane Risk of Bias Tool. Eight studies involving 2,314 participants met the inclusion criteria. SDM interventions improved treatment adherence in most studies, with rates increasing by 9% (78% vs. 69%, p < 0.01). Quality of life, measured by the World Health Organization Quality-of-Life Scale Abbreviated Version (WHOQOL-BREF), improved by 8.03 points (p < 0.002), and self-esteem, measured via the Rosenberg Scale, increased by 4.06 points (p < 0.001). Additional outcomes included a statistically significant increase in problem-solving ability scores in the SDM group, from 106.68 to 124.00 (n = 29, p < 0.001), while perceived autonomy support, patient activation, and confidence in communicating with providers were also notably higher for SDM participants (p < 0.05). In conclusion, SDM interventions demonstrate significant benefits in improving treatment adherence, quality of life, and various psychological outcomes in individuals with schizophrenia. The findings suggest that SDM fosters greater patient engagement, enhances self-efficacy, and strengthens trust in healthcare providers, ultimately leading to better mental health management. Further research is needed to explore long-term effects and optimize SDM strategies for sustained adherence and improved patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.